Targeted mtDNA Analysis with Heteroplasmy: Known Familial Mutation

Test Information

Targeted Next Generation Sequencing (NGS) analysis for a specific variant previously identified in a family member. Use of NGS allows for the reporting of heteroplasmy level.

Note: This test may not detect variants with a heteroplasmy of less than 3%.

 

 

Turnaround Time

4 weeks

CPT Code(s)

81403

Cost

$1,000

Variants

  • m.583G>A
  • m.616T>C
  • m.1494C>T
  • m.1555A>G
  • m.1606G>A
  • m.1630A>G
  • m.1644G>A
  • m.3243A>G
  • m.3243A>T
  • m.3256C>T
  • m.3258T>C
  • m.3260A>G
  • m.3271del
  • m.3271T>C
  • m.3280A>G
  • m.3291T>C
  • m.3302A>G
  • m.3303C>T
  • m.3376G>A
  • m.3460G>A
  • m.3635G>A
  • m.3697G>A
  • m.3700G>A
  • m.3733G>A
  • m.3890G>A
  • m.3902_3908inv
  • m.4171C>A
  • m.4298G>A
  • m.4300A>G
  • m.4308G>A
  • m.4332G>A
  • m.4450G>A
  • m.5521G>A
  • m.5537_5538insT
  • m.5650G>A
  • m.5690A>G
  • m.5703G>A
  • m.5728T>C
  • m.7445A>G
  • m.7471dup
  • m.7497G>A
  • m.7510T>C
  • m.7511T>C
  • m.8306T>C
  • m.8313G>A
  • m.8340G>A
  • m.8344A>G
  • m.8356T>C
  • m.8363G>A
  • m.8528T>C
  • m.8851T>C
  • m.8969G>A
  • m.8993T>G
  • m.8993T>C
  • m.9035T>C
  • m.9155A>G
  • m.9176T>G
  • m.9176T>C
  • m.9185T>C
  • m.9205_9206del
  • m.10010T>C
  • m.10158T>C
  • m.10191T>C
  • m.10197G>A
  • m.10663T>C
  • m.11777C>A
  • m.11778G>A
  • m.12147G>A
  • m.12258C>A
  • m.12276G>A
  • m.12294G>A
  • m.12315G>A
  • m.12316G>A
  • m.12706T>C
  • m.13042G>A
  • m.13051G>A
  • m.13094T>C
  • m.13379A>C
  • m.13513G>A
  • m.13514A>G
  • m.14459G>A
  • m.14482C>G
  • m.14482C>A
  • m.14484T>C
  • m.14487T>C
  • m.14495A>G
  • m.14568C>T
  • m.14674T>C
  • m.14709T>C
  • m.14710G>A
  • m.14849T>C
  • m.15579A>G

Clinical Information

Mitochondrial disorders represent a clinically heterogeneous group of conditions caused by pathogenic variants in either nuclear or mitochondrial DNA (mtDNA). Some mitochondrial disorders affect a single organ while most involve multiple organ systems. Mitochondrial disorders may present at any age and often present with prominent neurologic and myopathic features. Mitochondrial disorders have variable penetrance and severity of symptoms depending on the level of mutant mitochondria, or heteroplasmy, within a given individual or tissue type.

Indications

Molecular testing is useful to confirm the diagnosis of a mitochondrial condition in a family member.

Methodology

Next Generation Sequencing

Detection

Analysis for a familial variant can be performed using either Sanger sequencing or Next Generation Sequencing (NGS). Sanger sequencing is only able to detect levels of heteroplasmy above 20% while NGS can detect levels as low as 10%. For this reason, Sanger sequencing may be considered as a first step in evaluating for the presence of a familial variant. NGS testing may be reserved for those who appear to be affected or who would be expected to carry the familial variant, but have had negative Sanger sequencing results. As heteroplasmy levels vary from tissue to tissue, a negative blood test cannot completely rule out the chance that an individual carries the familial variant.

Specimen Requirements

The required sample type is peripheral blood collected in an EDTA (purple top) tube - at least 2-3ml for pediatric patients and 5-6ml for adult patients.

Transport Instructions

The specimen should be kept at room temperature and delivered via overnight shipping. If shipment is delayed by one or two days, the specimen should be refrigerated and shipped at room temperature. Do not freeze the specimen. Samples collected on Friday can be safely designated for Monday delivery.

Have Questions? Need Support?

Call our laboratory at 1-800-473-9411 or contact one of our Laboratory Genetic Counselors for assistance.
Robin Fletcher, MS, CGC
Kellie Walden, MS, CGC

Meet Reggie Roper

Reggie has been part of the GGC family for over 18 years. He has short stature, webbing of his hands, pulmonary stenosis, seizures and hydrocephalus along with developmental delay. He carried an initial diagnosis of cardiofaciocutaneous (CFC) syndrome; however, as genetic testing advanced, GGC made the diagnosis of Noon...

In The News